Tu sei qui

Curriculum Vitae

Expand | Collapse

Eleni Timotheadou

Assistant Professor, School of Medicine

Personal Information

- 2310693144
timotheadou@auth.gr
Scopus IDs36121313300, 23101746000
PubMed IDTimotheadou+E
Γνωστικό Αντικείμενο:
ΠΑΘΟΛΟΓΙΑ- ΟΓΚΟΛΟΓΙΑ
Επιστημονική Ειδίκευση:
- Ιατρική
- Ιατρικές υπηρεσίες
- ΠΑΘΟΛΟΓΙΚΗ ΟΓΚΟΛΟΓΙΑ

Education

Προπτυχιακές Σπουδές

1990	ΠΤΥΧΙΟ ΙΑΤΡΙΚΗΣ ΙΑΤΡΙΚΗ ΙΩΑΝΝΙΝΩΝ Greece ΠΑΘΟΛΟΓΙΑ, ΠΑΘΟΛΟΓΙΚΗ ΟΓΚΟΛΟΓΙΑ

Διδακτορικό Δίπλωμα

2004	ΔΔ ΙΑΤΡΙΚΗ ΑΡΙΣΤΟΤΕΛΕΙΟ Greece ΤΟΜΕΑΣ ΠΑΘΟΛΟΓΙΑΣ

Course Work

Courses of Winter semester of 2018–19 academic year

	TMĪMA IATRIKĪS
ΙΑ0321	Internal Medicine II

Courses of Spring semester of 2018–19 academic year

	TMĪMA IATRIKĪS
IA0376	Medical Oncology
ΙΑ0320	Internal Medicine I

Theses Supervised

Student Theses within AUTh

No results were found.

Administrative Work

Research Projects

2017–2017	Μια μελέτη φάσης 3 για την εκτίμηση της αποτελεσματικότητας και της ασφάλειας της δοσεταξέλης και της πρεδνιζόνης με ή χωρίς λεναλιδομίδη σε ασθενείς με ανθεκτικό στον ευνουχισμό καρκίνο του προστάτη
2016–2019	Πολυκεντρική, προοπτική μελέτη παρατήρησης για την εκτίμηση της κλινικής δραστηριότητας και του αντίκτυπου της θεραπείας με τραβεκτεδίνη στη βαρύτητα των συμπτωμάτων και την ποιότητα ζωής των ασθενών στα προχωρημένα σαρκώματα μαλακών μορίων σε πραγματικές συνθήκες στην Ελλάδα
2016–2018	Διπλά τυφλή, ελεγχόμενη με εικονικό φάρμακο, τυχαιοποιημένη μελέτη φάσης ΙΙΙ του συνδιασμού Τασελισίμπης και Φουλβεστράντης έναντι του συνδιασμού εικονικού φαρμάκου και φουλβερστράντης σε μετμμηνοπαυσιακές γυναίκες με θετικούς οιστρογονικούς υποδοχείς και HER2 αρνητικό τοπικά προχωρημένο ή μεταστατικό καρκίνο του μαστού που έχουν εμφανίσει υποτροπή ή εξέλιξη της νόσου κατά ή μετά τη θεραπεία με αναστολέα αρωματάσης
2016–2024	Μελέτη καταγραφής νόσου για την προοπτική παρατήρηση των θεραπευτικών σχημάτων και των εκβάσεων τους σε ασθενείς με HER2 - θετικό ανεγχείρητο τοπικά προχωρημένο ή μεταστατικό καρκίνο του μαστού
2015–2018	Κλινική και εργαστηριακή έρευνα σε συμπαγείς όγκους και στη Γενετική του καρκίνου
2013–2018	Νεοπλασματικά νοσήματα-Επιστημονικά δεδομένα, διαχείριση και θεραπεία

Publications

2017

Without Type

Psyrri Amanda, Kalogeras Konstantine T, Wirtz Ralph M, Kouvatseas George, Karayannopoulou Georgia, Goussia Anna, Zagouri Flora, Veltrup Elke, Timotheadou Eleni, Gogas Helen, Koutras Angelos, et al (2017). Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. Journal of Translational Medicine. vol.15 no.1.

2016

Without Type

Dermitzakis Emmanouil V, Kimiskidis Vasileios, Lazaridis George, Alexopoulou Zoi, Timotheadou Eleni, Papanikolaou Alexandros, Romanidou Ourania, Georgiadis George, Kalogeras Konstantine T, Tsiptsios Iakovos, Tarlatzis Vasileios, et al (2016). The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer. BMC Neurology. vol.16 no.1.
Stavridi Flora, Kalogeras Konstantine T, Pliarchopoulou Kyriaki, Wirtz Ralph M, Alexopoulou Zoi, Zagouri Flora, Veltrup Elke, Timotheadou Eleni, Gogas Helen, Koutras Angelos, Lazaridis Georgios, et al (2016). Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. PLOS ONE. vol.11 no.10 p.e0164013.

2015

Without Type

Papaxoinis George, Kotoula-Dimitriadou Vasiliki, Alexopoulou Zoi, Kalogeras Konstantine T, Zagouri Flora, Timotheadou Eleni, Gogas Helen, Pentheroudakis George, Christodoulou Christos, Koutras Angelos, Bafaloukos Dimitrios, et al (2015). Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. Plos One. vol.10 no.10 p.e0140293.

2014

Without Type

Lakis S, Kotoula-Dimitriadou Vasiliki, Eleftheraki AG, Batistatou A, Bobos M, Koletsa Triantafyllia, Timotheadou Eleni, Chrisafi S, Pentheroudakis G, Koutras A, Zagouri F, et al (2014). The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. Breast. Vol.23 no.3 p.234-243.

2013

Without Type

Fountzilas Georgios, Dafni U, Bobos M, Kotoula-Dimitriadou Vasiliki, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos Ioannis, Koletsa Triantafyllia, Tsolaki E, Televantou D, et al (2013). Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer. vol. 13 p. 163.

2011

Without Type

Fountzilas Georgios, Kourea H. P, Bobos M, Televantou D, Kotoula-Dimitriadou Vasiliki, Papadimitriou C, Papazisis K. T, Timotheadou Eleni, Efstratiou I, Koutras A, Pentheroudakis G, et al (2011). Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Research. vol.31 no.9 p.3007-3018.
Timotheadou Eleni (2011). New agents targeting angiogenesis in glioblastoma. Chemotherapy Research and Practice. vol.2011 p.878912.

2010

Without Type

Bafaloukos Dimitrios, Linardou Helena, Aravantinos Gerasimos, Papadimitriou Christos, Bamias Aristotelis, Fountzilas Georgios, Kalofonos Haralambos P, Kosmidis Paris, Timotheadou Eleni, Makatsoris Thomas, Samantas Epaminondas, et al (2010). A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Medicine. Published Version. vol.8 no.3.
Bamias Aristotelis, Karadimou Alexandra, Lampaki Sofia, Lainakis George, Malettou Lia, Timotheadou Eleni, Papazisis Georgios, Andreadis Charalambos, Kontovinis Loukas, Anastasiou Ioannis, Stravodimos Kostas, et al (2010). Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer. Published Version. vol.10 p.45.

2009

Without Type

2008

Without Type

Aravantinos Gerasimos, Fountzilas Georgios, Bamias Aristotelis, Grimani Irene, Rizos Spyridon, Kalofonos Haralabos, Skarlos Dimosthenis V, Economopoulos Theofanis, Kosmidis Paris, Skarlos Dimosthenis, Economopoulos Theofanis, et al (2008). Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. European Journal of Cancer. Published Version. vol.44 no.15 p.2169-2177.
Koutras A. K, Kalogeras K. T, Dimopoulos M, Wirtz R. M, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, et al (2008). Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. British Journal of Cancer. Published Version. vol.99 no.11 p.1775-1785.
Papadimitriou C. A, Papakostas P, Timotheadou Eleni, Aravantinos G, Bamias A, Fountzilas Georgios (2008). Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Cancer Investigation. vol.26 no.5 p.491-498.
Papadimitriou Christos, Papakostas Pavlos, Timotheadou Eleni, Aravantinos Gerasimos, Bamias Aristotelis, Fountzilas Georgios (2008). Adjuvant Dose-Dense Sequential Chemotherapy with Epirubicin, CMF and Weekly Paclitaxel in Patients with Resected High-Risk Breast Cancer: a Hellenic Cooperative Oncology Group (HeCOG) Study. Cancer Investigation. Published Version. vol.26 no.5 p.491-498.

2007

Without Type

Harrison M. L, Obermueller E, Maisey N. R, Hoare S, Edmonds K, Li N. F, Chao D, Hall K, Lee C, Timotheadou Eleni, Charles K, et al (2007). Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. Journal of Clinical Oncology. vol.25 no.29 p.4542-4549.
Malamou-Mitsi Vassiliki, Crikoni Olga, Timotheadou Eleni, Aravantinos Gerassimos, Vrettou Eleni, Agnantis Niki, Fountzilas Georgios (2007). Prognostic Significance of HER-2, p53 and Bcl-2 in Patients with Epithelial Ovarian Cancer. Anticancer Research. Published Version. vol.27 no.2 p.1157-1165.
Pectasides D, Dafni U, Aravantinos G, Timotheadou Eleni, Skarlos D. V, Pavlidis N, Gaglia A, Kalofonos H. P, Fountzilas Georgios (2007). A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin. Anticancer Research. vol.27 no.6C p.4411-4417.
Timotheadou Eleni, Skarlos Dimosthenis-Vasilios, Samantas Epaminondas, Papadopoulos Savvas, Murray Sam, Skrickova Jana, Christodoulou Christos, Papakonstantinou Christos, Pectasides Dimitrios, Papakostas Pavlos, Kaplanova Java, et al (2007). Evaluation of the Prognostic Role of a Panel of Biomarkers in Stage IB-IIIA Non-small Cell Lung Cancer Patients. Anticancer Research. Published Version. vol.27 no.6C p.4481-4489.

2006

Without Type

Fountzilas Georgios, Pectasides Dimitrios, Christodoulou Christos, Timotheadou Eleni, Ecomomopoulos Theofanis, Papacostas Pavlos, Papadimitriou Christos, Gogas Helen, Efstratiou Ioannis, Skarlos Dimosthenis (2006). Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Medical Oncology. Published Version. vol.23 no.4 p.479-488.
Murray S, Timotheadou Eleni, Linardou H, vrettou A.V, Kostopoulos Ioannis, Skrickova J, Papakonstantinou Christos, Christodoulou C, Pectasides D, Samantas E, Papacostas P, et al (2006). Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer. Published Version. vol.52 no.2 p.225-233.

2005

Without Type

Fountzilas Georgios, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos H.P, Siafaka V, et al (2005). Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology. Published Version. vol.16 no.11 p.1762-1771.
Timotheadou Eleni, Papakostas Pavlos, Tsavdaridis Dimitris, Basdanis Georgios, Kalofonos Haralambos, Aravantinos Gerasimos, Bafaloukos Dimitrios, Fountzilas Georgios (2005). Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer : a phase II study by the Hellenic Cooperative Oncology Group (HeCOG). Tumori. Published Version. vol.91 no.4 p.309-313.

2004

Without Type

Briasoulis E, Pentheroudakis G, Timotheadou Eleni, Rammou D, Pavlidis N, Fountzilas Georgios (2004). Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study. Anticancer Drugs. Published Version. vol.15 no.8 p.747-752.
Razis Evangelia, Kosmidis Paris, Aravantinos Gerassimos, Bakoyiannis Charalambos, Janinis Jim, Timotheadou Eleni, Christodoulou Christos, Fountzilas Georgios (2004). Second Line Chemotherapy with 5 Fluorouracil and Vinorelbine in Anthracycline and Taxane Pretreated Patients with Metastatic Breast Cancer. Cancer Investigation. Published Version. vol.22 no.1 p.10-15.

2001

Without Type

Fountzilas Georgios, Tsavdaridis D, Kalogera-Fountzila Anna, Christodoulou Ch, Timotheadou Eleni, Kalofonos Ch, Kosmidis P, Adamou A, Papakostas P, Gogas H, Stathopoulos G, et al (2001). Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. Annals of Oncology. Published Version. vol.12 no.11 p.1545-1551.

Aggiornato: 2018-10-15